The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain ...

A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle ...

They include very small molecules, such as urea, and complex structures, such as Taxol. As they may only be isolable in small quantities, have interesting biological activity and chemical ...

Apr. 18, 2025 — A new study suggests that early-life exposure to two widespread environmental pollutants -- small particle air pollution and outdoor artificial light at night -- could increase ...

CSU is stated to be a chronic inflammatory skin condition leading to recurring itch and severe hives. Credit: Andrey_Popov/Shutterstock. Sanofi and Regeneron’s ...

The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which is approved across several indications, including atopic ...

It could see competition from Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) – already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral ...

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU. On April 18, 2025, the FDA approved a resubmitted ...

The following is a summary of “Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines,” published in the ...